<DOC>
	<DOC>NCT00553254</DOC>
	<brief_summary>To assess the safety and efficacy of PF-00299804 in patients with advanced lung cancer.</brief_summary>
	<brief_title>Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Advanced NSCLC Prior treatment with and failure of at least one regimen of chemotherapy and erlotinib or gefitinib Prior treatment with no more than two chemotherapy regimens, including adjuvant treatment Measurable disease Chemotherapy, radiotherapy, biological or investigational agents within 4 weeks of baseline disease assessment Patients who lack of tolerance of erlotinib therapy Patients with known brain Metastases Patients with demonstrated history of or presence of interstitial lung disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>